The DOI matches its Crossref record; 323 of the 323 references it cites were found in a registry or an index.
Primary biliary cholangitis
Abstract
Primary biliary cholangitis is an autoimmune liver disease that predominantly affects women. It is characterised by a chronic and destructive, small bile duct, granulomatous lymphocytic cholangitis, with typical seroreactivity for antimitochondrial antibodies. Patients have variable risks of progressive ductopenia, cholestasis, and biliary fibrosis. Considerations for the cause of this disease emphasise an interaction of chronic immune damage with biliary epithelial cell responses and encompass complex, poorly understood genetic risks and environmental triggers. Licensed disease-modifying treatment focuses on amelioration of cholestasis, with weight-dosed oral ursodeoxycholic acid. For patients who do not respond sufficiently, or patients with ursodeoxycholic acid intolerance, conditionally licensed add-on therapy is with the FXR (NR1H4) agonist, obeticholic acid. Off-label therapy is recognised as an alternative, notably with the pan-PPAR agonist bezafibrate; clinical trial agents are also under development. Baseline characteristics, such as young age, male sex, and advanced disease, and serum markers of liver injury, particularly bilirubin and ALP, are used to stratify risk and assess treatment responsiveness. Parallel attention to the burden of patient symptoms is paramount, including pruritus and fatigue.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Primary biliary cholangitis is a chronic, autoimmune, cholestatic disease that mainly affects women aged 40-70 years.”
From Primary biliary cholangitis. (2024) · cites this paper as [1]
In the citing paper
“Primary biliary cholangitis is a chronic autoimmune, cholestatic, slowly progressing disease that can lead to cirrhosis and liver failure without early diagnosis and appropriate treatment.1”
From Primary biliary cholangitis. (2024) · cites this paper as [1]
In the citing paper
“Cigarette smoking, urinary tract infections, nail polish, and hair dyes were significantly associated with increased risk of primary biliary cholangitis.1,[24][25][26][27][28][29][30]”
From Primary biliary cholangitis. (2024) · cites this paper as [1]
In the citing paper
“This hypothesis is plausible because apoptotic BECs uniquely retain intact PDC-E2, while other cells do not due to glutathione modifications of PDC-E2 in their mitochondria.1,49”
From Primary biliary cholangitis. (2024) · cites this paper as [1]
In the citing paper
“Younger male patients (age <45 years), those with histologically advanced fibrosis, and those with anti-gp210 or anti-sp100 autoantibodies have a higher rate of progression. 1”
From Primary biliary cholangitis. (2024) · cites this paper as [1]
Citations
Cites
Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity
Markle, J. G. M., Frank, D. N., Mortin-Toth, S., Robertson, C. E., Feazel, L. M., Rolle-Kampczyk, U., von Bergen, M., McCoy, K. D., Macpherson, A. J., & Danska, J. S. (2013) · Science · doi:10.1126/science.1233521 · Cited by 2,025
Measuring the Functional Impact of Fatigue: Initial Validation of the Fatigue Impact Scale
Fisk, J. D., Ritvo, P. G., Ross, L., Haase, D. A., Marrie, T. J., & Schlech, W. F. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.supplement_1.s79 · Cited by 1,541
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationImai, T., Hieshima, K., Haskell, C., Baba, M., Nagira, M., Nishimura, M., Kakizaki, M., Takagi, S., Nomiyama, H., Schall, T. J., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80438-9 · Cited by 1,445
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
The X-files in immunity: sex-based differences predispose immune responses
Fish, E. N. (2008) · Nature Reviews Immunology · doi:10.1038/nri2394 · Cited by 1,162
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Adam, R., Karam, V., Delvart, V., O’Grady, J., Mirza, D., Klempnauer, J., Castaing, D., Neuhaus, P., Jamieson, N., Salizzoni, M., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.04.015 · Cited by 877
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Cited by
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Hirschfield, G. M., Bowlus, C. L., Mayo, M. J., Kremer, A. E., Vierling, J. M., Kowdley, K. V., Levy, C., Villamil, A., Ladrón de Guevara Cetina, A. L., Janczewska, E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312100 · Cited by 286
Self-citationRecent advances in clinical practice: Epidemiology of autoimmune liver diseases
Trivedi, P. J., & Hirschfield, G. M. (2021) · Gut · doi:10.1136/gutjnl-2020-322362 · Cited by 244
Self-citationHe, Z., Ma, Y., Yang, S., Zhang, S., Liu, S., Xiao, J., Wang, Y., Wang, W., Yang, H., Li, S., et al. (2022) · Microbiome · doi:10.1186/s40168-022-01269-0 · Cited by 190
Tanaka, A., Ma, X., Takahashi, A., & Vierling, J. M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01303-5 · Cited by 177
Tanaka, A., Hirohara, J., Nakano, T., Matsumoto, K., Chazouillères, O., Takikawa, H., Hansen, B. E., Carrat, F., & Corpechot, C. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.010 · Cited by 148
Metadata
- Authors
- Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M.
- Affiliations
- Peking University First Hospital (CN)
- University of California, Davis (US)
- University of Toronto (CA)
- Corresponding author
- Hirschfield, Gideon M
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 396
- Issue
- 10266
- Pages
- 1915-1926
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2753306570
- Cited by
- 253
- References
- 323
- Citations by year
- 2026: 28 · 2025: 48 · 2024: 58 · 2023: 46 · 2022: 46 · 2021: 22 · 2020: 1
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (DK090019)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, autoimmune liver disease, antimitochondrial antibodies, cholestasis, biliary fibrosis, ductopenia, ursodeoxycholic acid, obeticholic acid, FXR agonists, bezafibrate, PPAR agonists, disease-modifying therapy, risk stratification, pruritus, fatigue, sex differences
- MeSH terms
- Autoimmune Diseases, Chenodeoxycholic Acid, Cholagogues and Choleretics, Cholangitis, Fatigue, Humans, Pruritus, Risk Factors, Ursodeoxycholic Acid, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary biliary cholangitis. https://app.cochat.ai/papers/10.1016/s0140-6736(20)31607-x
- The paper
- Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020). Primary biliary cholangitis. The Lancet. https://doi.org/10.1016/s0140-6736(20)31607-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.